Skip to main content
kainos loboratories,inc logo

kainos loboratories,inc — Investor Relations & Filings

Ticker · 4556 ISIN · JP3205650009 T Manufacturing
Open in API
Filings indexed 65 across all filing types
Latest filing 2022-08-03 Report Publication Anno…
Country JP Japan
Listing T 4556

About kainos loboratories,inc

https://www.kainos.co.jp/en/

Kainos Laboratories, Inc. is a company focused on the development, manufacture, marketing, and distribution of in-vitro diagnostics and pharmaceuticals. As a pioneer in its field, the company specializes in creating innovative clinical testing reagents for biochemical, immunological, and genetic analysis. These diagnostic tools are used to examine biological samples, such as blood and urine, to provide data on a patient's health status. The company is committed to developing and supplying novel products to meet the needs of the medical and healthcare communities.

Recent filings

Filing Released Lang Actions
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, specifically confirming the accuracy of the contents of the First Quarter Report (第１四半期報告書). Since it is a regulatory filing confirming the validity of a report rather than the quarterly report itself, and it does not fit into specific categories like AGM or M&A, it falls under the general regulatory filing category.
2022-08-03 Japanese
四半期報告書－第48期第1四半期(令和4年4月1日－令和4年6月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for KAINOS Laboratories, Inc. covering the first quarter of the 48th fiscal year (April 1, 2022, to June 30, 2022). It contains detailed financial statements, including the balance sheet and income statement, as well as management analysis and notes. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2023
2022-08-03 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, Article 24-4-2, Paragraph 1. It serves as an officer's certification regarding the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report, should be classified as Regulatory Filings (RNS) rather than the report itself. FY 2021
2022-06-17 Japanese
内部統制報告書－第47期(令和3年4月1日－令和4年3月31日)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act of Japan. It details the company's framework, evaluation scope, and results regarding internal controls over financial reporting. As this is a specific regulatory filing required by Japanese law regarding internal control systems and does not fit into the other categories like 10-K (Annual Report) or ER (Earnings Release), it is classified as a Regulatory Filing.
2022-06-17 Japanese
有価証券報告書－第47期(令和3年4月1日－令和4年3月31日)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It contains detailed financial statements, management discussion, and corporate information for the fiscal year ending March 31, 2022. It is not an announcement or a summary, but the full statutory filing. FY 2022
2022-06-17 Japanese
有価証券届出書（組込方式）
Share Issue/Capital Change Classification · 98% confidence The document is a '有価証券届出書' (Securities Registration Statement) filed with the Kanto Local Finance Bureau by KAINOS Laboratories, Inc. This document is a formal regulatory filing required under the Financial Instruments and Exchange Act of Japan when a company intends to issue new shares or dispose of treasury shares (in this case, a third-party allotment of treasury shares to Sysmex Corporation). It contains detailed information about the offering, the purpose of the funds, and the relationship with the allottee. It is a primary regulatory filing rather than an announcement of a report.
2022-02-25 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.